bpc 157 sermorelin: Frequently asked questions

BPC-157 has a half-life of approximately 4 hours, meaning daily dosing maintains consistent tissue-level concentration. Missing 2–3 days resets local VEGF upregulation but doesn't reverse prior gains. Resume at your standard dose without compensatory doubling. Sermorelin has a similar short half-life but works through pulsatile GH release, so missing doses reduces cumulative IGF-1 elevation. If you miss more than 5 consecutive sermorelin doses, expect a 10–15% drop in IGF-1 levels that takes 7–10 days to recover once dosing resumes.

Administer BPC-157 immediately. Even delayed initiation produces measurable benefit during the proliferative phase (days 4–21). Begin sermorelin concurrently to optimize the remodeling phase that follows. Late starts reduce the total benefit window but don't eliminate efficacy. Tissue remodeling continues for 6–12 months post-injury, and GH optimization affects that entire timeline.

NSAIDs inhibit COX-2 enzymes, which are necessary for the inflammatory phase of healing. Chronic NSAID use during the first 7–10 days post-injury can delay recovery by 20–30%. BPC-157 modulates inflammation without suppressing it entirely, making it mechanistically compatible. Corticosteroid injections directly suppress collagen synthesis and should be avoided during active BPC-157 protocols. If corticosteroids were already administered, wait 10–14 days before starting BPC-157 to allow the anti-inflammatory effect to clear.

If the injury is purely localised soft tissue damage (e.g., patellar tendinopathy, tennis elbow), BPC-157 alone may suffice. Its angiogenic effects target the injury microenvironment directly. Add sermorelin if the injury involves muscle atrophy, bone involvement, or systemic deconditioning that requires whole-body anabolic signaling. A rotator cuff tear with muscle wasting benefits from sermorelin's IGF-1 elevation; a hamstring strain without systemic impact may not.

Verify peptide storage and reconstitution first. Temperature excursions or contaminated bacteriostatic water are the most common causes of ineffective peptides. If storage was correct, consider increasing BPC-157 to 500mcg daily or adding a second daily dose (250mcg morning, 250mcg evening). For sermorelin, bloodwork confirming IGF-1 elevation is the gold standard. If IGF-1 hasn't increased by at least 20–30% from baseline, you may be a non-responder or dosing too low. Some individuals require 300–400mcg sermorelin nightly to achieve therapeutic IGF-1 levels.

Switch to subcutaneous administration away from the injury site rather than stopping entirely. The peptide reaches the injury through systemic circulation. Localized injection speeds initial results but isn't mandatory. Rotate injection sites daily and ensure reconstitution used bacteriostatic water, not sterile saline, which increases irritation risk.

Tissue repair timelines depend on injury severity and vascularisation baseline. BPC-157's angiogenic effects take 7–10 days to manifest as new capillary formation, and sermorelin-induced IGF-1 elevation peaks at 2–4 weeks. Functional improvements. Reduced pain, increased range of motion. Typically lag behind cellular changes by 10–14 days. If no subjective improvement appears by week 3, verify peptide purity via COA documentation, confirm proper reconstitution and storage, and assess whether dosing aligns with body weight and injury type. Underdosing BPC-157 below 200 mcg daily or using degraded peptides are the most common protocol failures.

Administer both peptides as planned. Delayed initiation doesn't eliminate efficacy, it just means you're working through chronic inflammation rather than acute healing. BPC-157 still promotes angiogenesis in fibrotic tissue, and sermorelin still elevates systemic IGF-1. Expect 6–8 weeks instead of 4–6 weeks to see measurable improvement, and consider extending sermorelin dosing to 10–12 weeks if tissue remodelling hasn't plateaued by week 8.

Reconstituted peptides exposed to ambient temperature (20–25°C) for 12–24 hours experience partial denaturation. Bioactivity drops but doesn't reach zero immediately. If the vial was unopened and lyophilised (powder form), short-term temperature excursion is less damaging than for reconstituted solution. Once reconstituted, any exposure above 8°C for more than 6 hours compromises structural integrity. Discard and replace rather than risk using a degraded formulation. The cost of replacement is lower than continuing a protocol with unknown potency.

Stop both peptides immediately and consult your prescribing physician. Worsening pain, swelling, or loss of function during peptide therapy usually indicates improper diagnosis (e.g., treating a partial tear that's actually a complete rupture) or biomechanical overload (returning to activity too soon). Peptides accelerate healing. They don't replace rest, load management, or appropriate medical imaging. In our experience, this scenario is almost always user error (overtraining during recovery) rather than peptide-related adverse effects.

This paradoxical response occurs in 10–15% of users when doses exceed 300mcg. The GH pulse can trigger cortisol elevation in sensitive individuals. Reduce the dose to 150–200mcg and inject earlier in the evening (8pm instead of 10pm) to allow hormone levels to normalize before sleep onset. If symptoms persist after one week at reduced dosing, discontinue sermorelin and use BPC-157 as monotherapy.